Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer

K. Kairemo, M. Hodolic

. 2023 ; 24 (9) : . [pub] 20230504

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23011484

Prostate cancer is dependent on the action of steroid hormones on the receptors. Endocrine therapy inhibits hormone production or blocks the receptors, thus providing clinical benefit to many, but not all, oncological patients. It is difficult to predict which patient will benefit from endocrine therapy and which will not. Positron Emission Tomography (PET) imaging of androgen receptors (AR) may provide functional information on the likelihood of endocrine therapy response in individual patients. In this article, we review the utility of [18F]FDHT-PET imaging in prostate, breast, and other hormone-dependent cancers expressing AR. The methodologies, development, and new possibilities are discussed as well.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011484
003      
CZ-PrNML
005      
20230801133059.0
007      
ta
008      
230718s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms24098235 $2 doi
035    __
$a (PubMed)37175938
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kairemo, Kalevi $u Department of Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, 00180 Helsinki, Finland $u Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
245    10
$a Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer / $c K. Kairemo, M. Hodolic
520    9_
$a Prostate cancer is dependent on the action of steroid hormones on the receptors. Endocrine therapy inhibits hormone production or blocks the receptors, thus providing clinical benefit to many, but not all, oncological patients. It is difficult to predict which patient will benefit from endocrine therapy and which will not. Positron Emission Tomography (PET) imaging of androgen receptors (AR) may provide functional information on the likelihood of endocrine therapy response in individual patients. In this article, we review the utility of [18F]FDHT-PET imaging in prostate, breast, and other hormone-dependent cancers expressing AR. The methodologies, development, and new possibilities are discussed as well.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a androgenní receptory $7 D011944
650    12
$a nádory prostaty $x diagnostické zobrazování $7 D011471
650    _2
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a prostata $7 D011467
650    _2
$a dihydrotestosteron $7 D013196
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hodolic, Marina $u Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 9 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37175938 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133055 $b ABA008
999    __
$a ok $b bmc $g 1963725 $s 1197749
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 9 $e 20230504 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20230718
Back

Find record

Citation metrics

Archiving options